Navigation Links
Bedford Laboratories™ Issues Nationwide Voluntary Recall of Cytarabine for Injection, USP, 1 Gram Per Vial
Date:2/16/2012

BEDFORD, Ohio, Feb. 16, 2012 /PRNewswire/ -- Bedford Laboratories™ announces a nationwide voluntary recall for the following three lots of Cytarabine for Injection, USP:

Cytarabine for Injection, USP 1 gram per vial – NDC #55390-133-01

  • Lot 2066986 – Exp. Date March 31, 2014
  • Lot 2111675 – Exp. Date December 31, 2013
  • Lot 2131148 – Exp. Date May 31, 2014

(Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO )

This voluntary market recall is being conducted due to a post-release investigation of the manufacturing area which determined a potential elevated risk of a lack of sterility assurance for these specific lots.  To date, there have been no reports of any adverse events for the lots being recalled. 

Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine is indicated in the prophylaxis and treatment of meningeal leukemia.

Initial recall notification of the Cytarabine for Injection lots listed above were sent to impacted wholesalers and distributors by overnight courier and arranged for return of all recalled product.  Hospitals, emergency rooms, clinics, physician offices and other healthcare facilities and providers should not use the product lots listed above for patient care and should immediately quarantine any product for return.  Should wholesalers/distributors/retailers still have product which is being recalled, they should stop use and contact Bedford Laboratories Client Services at 800.562.4797. 

Bedford Laboratories has informed the U.S. Food and Drug Administration (FDA) of its actions and is maintaining ongoing discussion with the agency.  This voluntary recall is being conducted with the knowledge of the FDA.

Hospitals, emergency rooms, clinics, physician offices and other healthcare facilities and providers, or patients with product quality compliance, medical or other questions concerning the use of the product or reasons for this recall should contact the Client Services Department at 800.562.4797 between 8am and 5pm EST Monday - Friday.  Any adverse reactions experienced with any of the lots reported in this release should be also reported to 800.521.5169.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or regular mail or by fax.

About Bedford Laboratories
Bedford Laboratories is located in Bedford, OH and began in 1993 as a division of Ben Venue Laboratories. Bedford Laboratories supplies an extensive selection of critical-care and medically necessary multisource and specialty injectable products to the healthcare marketplace. For more information, please visit http://www.BedfordLabs.com.

About Ben Venue Laboratories, Inc.
Ben Venue Laboratories, Inc. was founded in 1938 and is a leading manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. Ben Venue is located in Bedford, Ohio and employs more than 1,300 people.  For more information, visit www.benvenue.com.

Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.  Please visit http://us.boehringer-ingelheim.com.

 


'/>"/>
SOURCE Bedford Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection
2. Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP
3. Bedford Laboratories™ to Begin Shipping Dactinomycin for Injection USP 500 mcg (0.5 mg)
4. Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial
5. Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P.
6. Bedford Laboratories™ Issues Guidance on 2011 Voluntary Recall of Polymyxin B for Injection USP and Vecuronium Bromide for Injection Related to Glass Particulates
7. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
8. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
9. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
10. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 On Wednesday, February 22, 2017, ... out of nine sectors finished the trading sessions in green, ... closing. Major US indices were also mixed at the close ... 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average ... 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com ...
(Date:2/23/2017)... 2017 ML Capital Group, Inc. (USOTC: MLCG) ... Highlife Tours , a Colorado -based cannabis ... Puration, Inc. (USOTC: PURA) to enter Colorado,s ... Colorado Highlife Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... and VANCOUVER, British Columbia ... OGXI ) today announced its year end ... In January 2017, OncoGenex, and Achieve Life Science, ... they have entered into a definitive merger agreement under ... Upon completion of the proposed merger, Achieve,s stockholders are ...
Breaking Medicine Technology:
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... it will soon begin franchising throughout the U.S. starting this spring. Current Meditation ... the practice of meditation mainstream. Current Meditation will be the first meditation concept ...
(Date:2/23/2017)... , ... February 23, 2017 , ... CALNOC, the nation’s ... FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, ... and CEO of the Virginia Mason Health System in Seattle since 2000. In addition ...
(Date:2/23/2017)... ... ... Thomas Vas-Don suffered from severe injury due to an industrial ... recover. In “ Origin & Insertion Charts for Massage Therapists ” (published by Xlibris ... anatomy , trigger points and referral pain patterns . , In this ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based ... velvet, announced its products are coming soon to Amazon.com, the world’s largest online retailer. ... as a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which ...
Breaking Medicine News(10 mins):